Evidence map›Paper›PMID 36594172›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Prevalence of Testing for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Among Medicaid Enrollees Treated With Medications for Opioid Use Disorder in 11 States, 2016-2019.

Katherine Ahrens, Michael Sharbaugh, Marian P Jarlenski, Lu Tang, Lindsay Allen, Anna E Austin, Andrew J Barnes, Marguerite E Burns, Sarah Clark, Kara Zivin and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Katherine AhrensPublic Health Program, Muskie School of Public Service, University of Southern Maine, Portland, Maine, USA.
Michael SharbaughDepartment of Health Policy and Management, University of Pittsburgh, School of Public Health, Pittsburgh, Pennsylvania, USA.
Marian P JarlenskiDepartment of Health Policy and Management, University of Pittsburgh, School of Public Health, Pittsburgh, Pennsylvania, USA.
Lu TangDepartment of Biostatistics, University of Pittsburgh, School of Public Health, Pittsburgh, Pennsylvania, USA.
Lindsay AllenHealth Policy, Management, and Leadership Department, School of Public Health, West Virginia University, Morgantown, West Virginia, USA.
Anna E AustinDepartment of Maternal and Child Health, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Andrew J BarnesHealth Behavior and Policy Department, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Marguerite E BurnsDepartment of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, USA.
Sarah ClarkDepartment of Pediatrics, School of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Kara ZivinDepartment of Psychiatry, School of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Aimee MackGovernment Resource Center, Ohio Colleges of Medicine, Ohio State University, Columbus, Ohio, USA.
Gilbert LiuGovernment Resource Center, Ohio Colleges of Medicine, Ohio State University, Columbus, Ohio, USA.
Shamis MohamoudHilltop Institute, University of Maryland Baltimore County, Baltimore, Maryland, USA.
Mary Joan McDuffieCenter for Community Research & Service, Biden School of Public Policy and Administration, University of Delaware, Newark, Delaware, USA.
Lindsey HammerslagCollege of Medicine, Institute for Biomedical Informatics, University of Kentucky, Lexington, Kentucky, USA.
Adam J GordonProgram for Addiction Research, Clinical Care, Knowledge and Advocacy, Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Julie M DonohueDepartment of Health Policy and Management, University of Pittsburgh, School of Public Health, Pittsburgh, Pennsylvania, USA.
Writing Committee for Medicaid Outcomes Distributed Research Network

Funding

Examining the quality of opioid use disorder treatment in a Medicaid research networkR01DA048029 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DONOHUE, JULIE MARIE · 2019 to 2021
$3.5M
NIDA NIH HHS R01 DA048029
6 · The paper itself

Abstract

backgroundLimited information exists about testing for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) among Medicaid enrollees after starting medication for opioid use disorder (MOUD), despite guidelines recommending such testing. Our objectives were to estimate testing prevalence and trends for HIV, HBV, and HCV among Medicaid enrollees initiating MOUD and examine enrollee characteristics associated with testing.

methodsWe conducted a serial cross-sectional study of 505 440 initiations of MOUD from 2016 to 2019 among 361 537 Medicaid enrollees in 11 states. Measures of MOUD initiation; HIV, HBV, and HCV testing; comorbidities; and demographics were based on enrollment and claims data. Each state used Poisson regression to estimate associations between enrollee characteristics and testing prevalence within 90 days of MOUD initiation. We pooled state-level estimates to generate global estimates using random effects meta-analyses.

resultsFrom 2016 to 2019, testing increased from 20% to 25% for HIV, from 22% to 25% for HBV, from 24% to 27% for HCV, and from 15% to 19% for all 3 conditions. Adjusted rates of testing for all 3 conditions were lower among enrollees who were male (vs nonpregnant females), living in a rural area (vs urban area), and initiating methadone or naltrexone (vs buprenorphine). Associations between enrollee characteristics and testing varied across states.

conclusionsAmong Medicaid enrollees in 11 US states who initiated medications for opioid use disorder, testing for human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and all 3 conditions increased between 2016 and 2019 but the majority were not tested.

Indexed as

Hepatitis CHIV InfectionsOpioid-Related DisordersCross-Sectional StudiesFemaleHepacivirusHepatitis B virusHIVHumansMaleMedicaidPrevalenceUnited StateshepatitisHIVMedicaidopioid use disordertesting

Identifiers

PMID36594172
PMCPMC10209438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.